Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Growth at a CAGR of 8.5% 2021

ResearchMoz added Latest Research Report titled " Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line " to it's Large Report database.

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=372992

Scope
  • The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5%.
  • How will immunotherapies such as Keytruda affect growth?
  • What effect will patent expirations of Tarceva and Alimta have on market value?
  • The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market.
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
  • What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
  • Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
Read All Therapeutic Area Market Research Reports @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

Table of Contents

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Adenocarcinoma
2.3.2 Squamous Cell Carcinoma
2.3.3 Large Cell Carcinoma
2.3.4 Immunotherapy
2.4 Symptoms
2.5 Diagnosis
2.6 Prognosis
2.7 Treatment
2.7.1 Treatment Algorithm
2.7.2 First-Line Treatment
2.7.3 Maintenance Therapy
2.7.4 Second-Line Treatment
2.7.5 Third-Line Therapy
2.7.6 Adjuvant Therapy
2.8 Marketed Product Heatmaps
3 Marketed Products
3.1 Overview
3.2 Chemotherapies
3.3 Alimta – Eli Lilly
3.4 Abraxane – Celgene Corporation
3.5 Tarceva – Roche

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Growth at a CAGR of 8.5% 2021 Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Growth at a CAGR of 8.5% 2021 Reviewed by Sagar Jagtap on 02:26 Rating: 5

No comments:

Powered by Blogger.